terbinafine –

$24.00

SKU: USUK463O37 Category: Tag:

Description

Brief Product

terbinafine spray it is used to treat foot fungus, fungus on the body, multi-colored lichen, candidiasis of the skin. *

Lamisil Spray is conveniently applied to areas affected by the fungus. There is no need to touch the infected areas, therefore, after treatment, the hands remain clean.

The active substance of the spray Lamisil terbinafine has a fungicidal effect by which it fights against an infection that causes foot fungus (mycosis). *

* Medical Instructions, RU No  ÑŸ N016003 / 02 of 12/22/2009

Description

Spray for external use in the form of a clear, colorless or light yellow liquid with a characteristic odor.

Latin name

Lamisil

Release form

Spray for external use

Pharmacological action

Antifungal drug for external use, having a wide spectrum of antifungal activity. In small concentrations, terbinafine has a fungicidal effect against dermatophytes (Trychophyton rubrum, Trychophyton mentagrophytes, Trychophyton verrucosum, Trychophyton violaceum, Trychophyton tonsurans, Microsporum canis, Epidermophyton floccosum), mold (mainly Candida albicoricum fungi) and fungi.

Activity against yeast fungi, depending on their type, can be fungicidal or fungistatic.

Terbinafine specifically modifies the early stage of sterol biosynthesis in fungi. This leads to a deficiency of ergosterol and to intracellular accumulation of squalene, which causes the death of the fungal cell.

The action of terbinafine is carried out by inhibiting the enzyme squalene epoxidase, located on the cell membrane of the fungus.

Terbinafine does not affect the human cytochrome P450 system and, accordingly, the metabolism of hormones or other drugs.

Indications

Prevention and treatment of fungal infections of the skin: foot fungal infections (tinea pedis) keratinization, cracks, itching and peeling of the skin caused by foot fungus inguinal epidermophytosis (tinea craris), fungal infections of smooth body skin (tinea corporis) caused by such dermatitis like Trichophyton (including T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis and Epidermophyton floccosum yeast infections of the skin, mainly those caused by Candida fungi (e.g. Candida albicans), in particular, diaper rash, multicolored lichen (Pityriasis versicolor), caused by Pityrosporum orbiculare (Malassezia furfur).

Contraindications

Hypersensitivity to terbinafine or to any of the inactive ingredients, included in the composition of the drug during breastfeeding for children under 18 years of age.

With caution, the drug is prescribed for patients with hepatic and / or renal failure, patients with chronic alcoholism, with suppression of bone marrow hematopoiesis, tumors, metabolic diseases, occlusive diseases of the limb vessels.

Use during pregnancy and lactation

Since the clinical experience with Lamisil® cream in pregnant women is very limited, it should not be used, unless absolutely necessary.

During pregnancy, the drug is used only if the intended benefit to the mother outweighs the potential risk to the fetus. It is necessary to consult a doctor.

In experimental studies of teratogenic properties of terbinafine have not been identified. To date, no malformations have been reported with the use of Lamisil®.

Terbinafine is excreted in breast milk, therefore, the drug should not be prescribed to nursing mothers. The baby should not be allowed to come into contact with any skin surface treated with Lamisil®.

Special instructions

A decrease in the severity of clinical manifestations is usually observed in the early days of treatment. In the case of irregular use or premature termination, there is a risk of recurrence of infection.

The drug is intended for external use only.

Avoid contact with eyes. it can cause irritation. In case of accidental contact with eyes, rinse immediately with running water, and if persistent irritation develops, consult a doctor.

With the development of allergic reactions, it is necessary to cancel the drug.

Lamisil ® Cream for external use contains cetyl and stearyl alcohols, which can cause local allergic reactions (contact dermatitis) at the application sites.

Caution should be exercised when applying Lamisil ® Spray to damaged skin, as ethanol, which is part of it, can cause irritation. Lamisil ® Spray is for external use only. Do not use Lamisil ® Spray for application to the face.

If Lamisil ® spray was accidentally introduced into the respiratory tract during inhalation, then in case of any symptoms and especially with their persistence, it is necessary to consult a doctor. Lamisil ® Spray contains propylene glycol, which in some cases can cause skin irritation. It should also be borne in mind that the drug contains 96% ethanol.

Impact on ability to drive vehicles and mechanisms

Not affected.

Composition of

1 g of spray contains:

Active ingredient:

10 mg of terbinafine hydrochloride

Excipients:

macrogol cetostearyl ether,

ethanol,

purified propyl azot,

,

water,

Side effects

Determination of frequency of side effects (WHO): very common ( 1/10), often ( 1/100 and <1/10), infrequently ( 1/1000 and <1/100), rarely ( 1/10 000 and <1/1000), very rare (<1/10 000), including individual messages. From the immune system: separate reports – hypersensitivity reactions (rash). From the eye: Rare – eye irritation. From the skin: often – skin peeling, itching infrequently – skin damage, crust formation, skin damage, pigmentation disorder, erythema, skin burning sensation rarely – skin dryness, contact dermatitis, eczema separate messages – rash. Local reactions: infrequently – pain, pain at application site, irritation at application site rarely – exacerbation of disease symptoms. In places of application of the drug itching can be observed, peeling of the skin, pain, irritation, change of skin pigmentation, burning, erythema, cork. These minor symptoms should be distinguished from hypersensitivity reactions such as a rash that occur in rare cases and require treatment discontinuation. In rare cases, the course of the fungal infection can be exacerbated. If any of these side effects are exacerbated, or if the patient has noticed any other side effects, tell your doctor. Drug Interaction The current drug interaction of Lamizil ® is unknown. Overdose No cases of overdose of Lamisil ® reported. Symptoms: occasional ingestion of 30 ml of Lamisil ® spray containing 300 mg of terbinafine hydrochloride is comparable to taking 1 tablet of Lamisil ® with a dosage of 250 mg (single dose for an adult). If you accidentally take more Lamisil ® spray inside, you can expect the same side effects to develop as with an overdose of Lamisil ® tablets (headache, nausea, epigastric pain and dizziness). It should also be borne in mind that the spray contains ethyl alcohol (28.87% (vol./about.). Treatment: activated charcoal, symptomatic therapy is necessary if necessary. Storage conditions At a temperature not exceeding 30 ° C (do not freeze). Term hodnosty 3 years active substance Terbinafine Terms of the pharmacy leave Terms of the pharmacy Over-the-counter